CRISPR genome editing, preclinical services

Biocytogen specializes in innovative biotechnologies focused on the development of genetically engineered mouse models and related services. Their proprietary technologies enable the creation of highly specific and customizable mouse models that are essential for preclinical research. These models are designed to mimic human diseases more accurately, facilitating better understanding of disease mechanisms and the evaluation of therapeutic interventions. Biocytogen's advanced gene editing techniques, including CRISPR/Cas9, allow for precise modifications in the mouse genome, which enhances the relevance and reliability of research outcomes.

In addition to their mouse model development, Biocytogen offers a range of services that support drug discovery and development processes. Their capabilities include high-throughput screening, pharmacokinetics, and toxicology studies, which are crucial for assessing the efficacy and safety of new therapeutics. The integration of these technologies not only accelerates the drug development timeline but also improves the translational potential of research findings from animal models to human applications. Overall, Biocytogen's commitment to advancing preclinical research through innovative technologies positions them as a key player in the biotechnology sector.

United States

Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ mice), and in vivo/in vitro preclinical validation studies. Biocytogen collaborates with more than 70% of the top 50 pharmaceutical and biotechnology companies worldwide. Together, we discover innovative medicines for a better, healthier world.

Biocytogen

Company Details